Anshul Maheshwari Sells 4,665 Shares of SiBone (NASDAQ:SIBN) Stock

SiBone (NASDAQ:SIBN) CFO Anshul Maheshwari sold 4,665 shares of the firm’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $18.65, for a total transaction of $87,002.25. Following the completion of the sale, the chief financial officer owned 251,895 shares of the company’s stock, valued at $4,697,841.75. The trade was a 1.82% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Anshul Maheshwari also recently made the following trade(s):

• On Thursday, July 2nd, Anshul Maheshwari sold 3,317 shares of SiBone stock. The stock was sold at an average price of $16.77, for a total transaction of $55,626.09.

SiBone Price Performance

Shares of SIBN stock opened at $19.91 on Thursday. SiBone has a 1 year low of $11.48 and a 1 year high of $21.89. The firm’s 50 day moving average is $17.31 and its 200-day moving average is $15.28. The firm has a market capitalization of $883.01 million, a price-to-earnings ratio of -58.56 and a beta of 0.66. The company has a current ratio of 9.15, a quick ratio of 7.55 and a debt-to-equity ratio of 0.20.

SiBone (NASDAQ:SIBN) last issued its quarterly earnings results on Monday, August 3rd. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.06. SiBone had a negative net margin of 6.85% and a negative return on equity of 8.23%. The business had revenue of $56.01 million during the quarter, compared to analyst estimates of $55.34 million. Sell-side analysts forecast that SiBone will post -0.4 EPS for the current fiscal year.

Institutional Trading of SiBone

Hedge funds and other institutional investors have recently modified their holdings of the company. Royal Bank of Canada boosted its position in shares of SiBone by 98.5% during the fourth quarter. Royal Bank of Canada now owns 1,483 shares of the company’s stock worth $29,000 after buying an additional 736 shares during the period. Versant Capital Management Inc raised its position in SiBone by 102.9% in the 2nd quarter. Versant Capital Management Inc now owns 1,749 shares of the company’s stock valued at $29,000 after buying an additional 887 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in SiBone by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,426 shares of the company’s stock valued at $343,000 after buying an additional 1,053 shares during the last quarter. Larson Financial Group LLC lifted its stake in SiBone by 42.3% in the 4th quarter. Larson Financial Group LLC now owns 3,569 shares of the company’s stock valued at $70,000 after acquiring an additional 1,061 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its stake in SiBone by 4.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 37,159 shares of the company’s stock valued at $733,000 after acquiring an additional 1,459 shares in the last quarter. Institutional investors and hedge funds own 98.11% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on SIBN. TD Cowen raised their target price on SiBone from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. Weiss Ratings lowered shares of SiBone from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, August 5th. UBS Group upped their target price on shares of SiBone from $24.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. Finally, Truist Financial reiterated a “buy” rating and issued a $23.00 target price (up from $21.00) on shares of SiBone in a report on Tuesday, August 4th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, SiBone has a consensus rating of “Moderate Buy” and an average price target of $24.17.

About SiBone

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.